Get the content you want anytime you want.
REGISTER NOW | SIGN IN
VIDEO

Using Synergistic Combination Drug Therapy to Battle Antibiotic Resistance

AUG 23, 2017 | CONTAGION® EDITORIAL STAFF


Edmond LaVoie, PhD, professor and chair, Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers University, co-founder of TAXIS Pharmaceuticals, shares how his team’s research on the development of MRSA prodrug, TXA709, can help inform the development of novel drugs to treat other drug-resistant bacteria. Dr. LaVoie explains the benefits of synergistic drug combination and how this allows for fewer possibilities for resistance to develop.
To stay informed on the latest in infectious disease news and developments, please sign up for our weekly newsletter.


FEATURED
The new test can differentiate between Lyme disease and 7 other tick-borne diseases.